Recurrent C. Difficile Infections (rCDI) – Market Outlook, Epidemiology, Competitive Landscape, and Market Forecast Report – 2021 To 2032

Recurrent C. Difficile Infections (rCDI) Market Outlook

Thelansis’s “Recurrent C. Difficile Infections (rCDI) Market Outlook, Epidemiology, Competitive Landscape, and Market Forecast Report – 2021 To 2032" covers disease overview, epidemiology, drug utilization, prescription share analysis, competitive landscape, clinical practice, regulatory landscape, patient share, market uptake, market forecast, and key market insights under the potential Recurrent C. Difficile Infections (rCDI) treatment modalities options for eight major markets (USA, Germany, France, Italy, Spain, UK, Japan, and China).

Recurrent C. Difficile Infections (rCDI) Overview

Clostridium difficile infection (CDI) is an anaerobic spore-forming bacillus that colonizes the intestinal tract in patients whose normal gut microbiota is disrupted by antibiotic therapy or any other reason. C difficile produces two major toxins—toxins A and B—that cause intestinal mucosal injury, diarrhea, and colitis. In some cases, fulminant infection leads to shock, ileus, and toxic megacolon. In high-income countries, C. difficile is the most common cause of infectious diarrhea in hospitalized patients. Between 20% and 35% of patients with C. difficile infection will fail initial antibiotic treatment, and, of these, 40–60% will have a second recurrence. Recurrence of C. difficile infection after initial treatment causes substantial morbidity and is a significant burden on health care systems. Antibiotics are the mainstay treatments for primary and recurrent CDI, with a recent trend toward vancomycin and fidaxomicin over metronidazole. Recurrent infections affect 15-35 percent of CDI patients. CDI is frequently a relapse of the same infection rather than a new strain infection. Following the first recurrence, second and subsequent recurrences are even more common.

• The incidence of Clostridium difficile infection ranges from 0.8 Mn to 1 Mn in the USA and is higher among females.

Geography Covered:

North America- the United States and Canada

Europe- EU5 (Germany, France, Italy, Spain, and the United Kingdom)

Other countries- Japan & China

Study Period: 2021-2032

Current Clinical Practice and Treatment Algorithm

This section of the study covers country-specific current clinical practice, the standard of care, and significant limitations around addressing the unmet needs. Retrospective analysis and bench-marking of clinical study outcomes are presented in terms of Pre-treatment & post-treatment clinical and demographic patient characteristics. Essentially, this section will cover the evolution of the current competitive landscape and its impact on the future treatment paradigm.

KOL Insights:

KOLs across 8 MM markets from the center of Excellence/ Public/ Private hospitals participated in the study. Insights around current treatment landscape, epidemiology, clinical characteristics, future treatment paradigm, and Unmet needs

Market Forecast: Patient Based Forecast Model (MS. Excel Based Automated Dashboard)

- Data Inputs with sourcing

- Market Event and Product Event

- Country-specific Forecast Model

- Market uptake and patient share uptake

- Attribute Analysis

- Analog Analysis

- Disease burden and pricing scenario

- Summary and Insights

NPV/ IRR Calculator-

Optimization of cash flow/ revenue flow concerning all fixed and variable investments throughout the product development process. The rate of return on an investment is a critical indicator to ensure the profitability and break-even of the project.

Competitive Landscape:

The competitive landscape includes country-specific approved as well as pipeline therapies. Any asset/product-specific designation or review such as Orphan drug designation, Fast track, Priority Review, Breakthrough Therapy Designation, Rare Pediatric Disease Designation, and Accelerated Approval are tracked and supplemented with analyst commentary.

Clinical Trial Assessment-

Detailed clinical trial data analysis and critical product positioning include trial design, primary outcomes, secondary outcomes, dosing and schedules, inclusion and exclusion criteria, recruitment status and essentially covers the reported adverse events. Majorly the trial analysis helps determine the potential of the critical assets and their probable filing and launch date.

Unmet Medical Needs Overview-

This report presents the most important clinical unmet needs in the treatment, according to Thelansis research and analysis. Other essential unmet needs identified through our study include decreased cost burden on patients, improved administration convenience, and improved patient compliance.

Visit our social media pages: